Solascure

Solascure company information, Employees & Contact Information

Explore related pages

Related company profiles:

Chronic wounds affect ~100m people around the world, impacting quality of life & placing a huge burden on health systems. Despite the many innovations in wound care over the years, chronic wound healing rates have barely improved. Change is needed – patients, practitioners, and regulators across the industry are in urgent need of high-impact innovations in chronic wound care. SolasCure is at the forefront of addressing this demand, aiming to shift the current treatment paradigm with a high impact therapeutic approach to debridement, with the goal of enabling dramatic improvements in healing rates and patients’ quality of life. Aurase Wound Gel aims to address the huge unmet need for easy & effective debridement to return wounds to healing. It combines the enzyme Tarumase with hydrogel to debride wounds, reduce biofilm & promote healing. Tarumase is a highly-specific fibrinolytic enzyme cloned from maggot saliva, perfectly optimised by evolution for wound bed preparation. After successful Phase IIa trials, SolasCure is preparing for the next phase of clinical development to bring Aurase Wound Gel one step closer to improving the lives of millions of patients suffering from chronic wounds. For more information, you can find our peer-reviewed publications here: Clinical: https://onlinelibrary.wiley.com/doi/10.1111/iwj.14805 Preclinical: https://onlinelibrary.wiley.com/doi/10.1111/iwj.14079 The importance of our innovative technology has been widely recognised: - Innovate UK Global Incubator Programme (Innovate UK, the UK’s Innovation Agency), Texas Medical Center, 2024 - Biomedical Catalyst Grant (Innovate UK, the UK’s Innovation Agency), 2024 - EIC Accelerator Grant (European Innovation Council), 2023 - Life Sciences Innovator (UK Department for Trade and Business), 2023 - EIT Health Catapult, Biotech Category (European Institute of Innovation & Technology), 2022 - Winner 2019 URGO Mentorship Programme. Visit us at www.solascure.com

Company Details

Employees
18
Founded
-
Address
Wellington House, East Road,united Kingdom
Phone
441223827959
Email
in****@****ure.com
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
HQ
Cambridge
Looking for a particular Solascure employee's phone or email?

Solascure Questions

News

SolasCure receives FDA Fast Track Designation for Aurase Wound Gel to treat calciphylaxis ulcers - Business Wire

SolasCure receives FDA Fast Track Designation for Aurase Wound Gel to treat calciphylaxis ulcers Business Wire

SolasCure publishes phase IIa clinical trial report in leading wound care journal - News-Medical

SolasCure publishes phase IIa clinical trial report in leading wound care journal News-Medical

Preliminary evidence supporting a new enzymatic debridement product for use in chronic wounds - Wiley Online Library

Preliminary evidence supporting a new enzymatic debridement product for use in chronic wounds Wiley Online Library

SolasCure selected for Innovate UK Global Incubator Programme in Houston - Cambridge Network

SolasCure selected for Innovate UK Global Incubator Programme in Houston Cambridge Network

SolasCure demonstrates proof-of-concept in Phase lla safety trial of Aurase Wound Gel - News-Medical

SolasCure demonstrates proof-of-concept in Phase lla safety trial of Aurase Wound Gel News-Medical

SolasCure Enrols First Patient in a Next Phase II Clinical Trial to Advance Aurase Wound Gel - Business Wire

SolasCure Enrols First Patient in a Next Phase II Clinical Trial to Advance Aurase Wound Gel Business Wire

Fish Skin Grafts: A New Frontier in Wound Healing - Drug Discovery News

Fish Skin Grafts: A New Frontier in Wound Healing Drug Discovery News

Treating chronic wounds effectively: The unmet need - Cambridge Network

Treating chronic wounds effectively: The unmet need Cambridge Network

Novan Therapeutics’ SB204 shows promise as a non- antibiotic treatment of acne vulgaris - Drug Discovery News

Novan Therapeutics’ SB204 shows promise as a non- antibiotic treatment of acne vulgaris Drug Discovery News

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant